US regulators approve Fresenius buyout of APP

By Associated Press
September 2, 2008 | Comments (0)

Recs

0

Special Offer!

Jan 12, Motley Fool Pro will accept new members for 10 days only. Your spot is reserved! To learn more, click below.

Motley Fool Pro

APP Pharmaceuticals Inc. said Tuesday U.S. regulators have cleared the way for its purchase by German dialysis-clinic operator Fresenius.

In July, Hamburg-based Fresenius announced its plan to purchase APP for $3.7 billion in cash, or $23 per share, plus potential contingent payments of $970 million, or $6 per share. APP said Tuesday it expects the deal to close by mid-September, now that the Federal Trade Commission has completed its review of the transaction. German authorities previously signed off on the deal.

APP makes injectable drugs, including heparin, used by patients on kidney dialysis. Fresenius' purchase of the company is expected to help lower its expenses.

Shares of APP Pharmaceuticals rose 15 cents to $23.82. Shares of Fresenius Medical Care AG fell 13 cents to $53.40

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

DocumentId: 718736, ~/articles/articlehandler.aspx, 1/8/2009 1:11:59 AM

Sign up for FREE Motley Fool site access to keep reading:

“US regulators approve Fresenius buyout of APP”

Signing up allows you to comment on articles and on the discussion boards.

It's completely FREE and will take only 10 seconds.

Privacy / Legal Information

We will use your email address only to keep you informed about updates to our web site and about other products and services that we think might interest you. The Motley Fool respects your privacy. Please read our Privacy Statement

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.